94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CASE REPORT article
Front. Oncol.
Sec. Neuro-Oncology and Neurosurgical Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1525401
Primary Intracranial High-grade Myofibroblastic Sarcoma: A case report and literature review Authors
Provisionally accepted- 1 Department of Medical Oncology, The First People’s Hospital of Longquanyi District, Chengdu, Chengdu, China
- 2 Department of Radiology, The First People's Hospital of Longquanyi District, Chengdu, Chengdu, China
- 3 Department of Pathology, The First People's Hospital of Longquanyi District, Chengdu, Chengdu, China
- 4 Department of Radiation Oncology and Department of Head & Neck Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
- 5 West China Hospital, Sichuan University, Chengdu, China
- 6 Abdominal Oncology Ward, Division of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
High-grade myofibroblastic sarcoma (HGMS) is exceedingly rare, highly aggressive with poor prognosis. There is no consensus yet on its definitions nowadays. Wide resection is the standard of care for most patients, while there is limited clinical information on its outcomes of treatment. Here, we present the first case of HGMS originating from the intracranium. Surgical excision of the tumor was performed, followed by adjuvant radiotherapy with a total dose of 60 Gy in 30 fractions. As of November 2024, a 24-month recurrence-free survival was achieved. This case may provide new evidence potentially be useful for the treatment of the rare primary intracranial HGMS.
Keywords: primary intracranial, high-grade myofibroblastic sarcoma, resection, Radiotherapy, case report
Received: 20 Dec 2024; Accepted: 11 Mar 2025.
Copyright: © 2025 He, Lv, Yuan, He, Du, Yang, Zhang and Wen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Feng Wen, West China Hospital, Sichuan University, Chengdu, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.